Risk factors of NSR (W24)
| . | Total (n = 48)∗ . | SROT (n = 27) . | NSR (n = 21) . | Univariable analysis . | |
|---|---|---|---|---|---|
| Unadjusted—OR [95% CI] . | P value† . | ||||
| Age, median (IQR), y | 58.5 (41-73.5) | 58 (34-74) | 60 (51-71) | 1.01 [0.98-1.04] | .69 |
| No. of therapeutic lines before TPO-RAs, n = 48 | .98 | ||||
| 1 | 11 (23.0) | 6 (22.2) | 5 (23.8) | 1 (reference) | |
| ≥2 | 37 (77.0) | 21 (77.8) | 16 (76.2) | 0.98 [0.25-3.81] | |
| Splenectomy history | 6 (12.5) | 2 (7.4) | 4 (19.0) | 2.88 [0.47-17.54] | .25 |
| Previous treatment with rituximab | 22 (45.8) | 12 (44.4) | 10 (47.6) | 1.12 [0.36-3.53] | .85 |
| Previous treatment with another TPO-RA | 14 (29.2) | 6 (22.2) | 8 (38.1) | 2.44 [0.66-9.07] | .18 |
| ITP duration at TPO-RA initiation | .19 | ||||
| Persistent | 18 (37.5) | 12 (44.4) | 6 (28.6) | 1 (reference) | |
| Chronic | 30 (62.5) | 15 (55.6) | 15 (71.4) | 2.30 [0.66-8.01] | |
| ITP duration at inclusion | .87 | ||||
| Persistent | 2 (4.2) | 1 (3.7) | 1 (4.8) | 1 (reference) | |
| Chronic | 46 (95.8) | 26 (96.3) | 20 (95.2) | 0.77 [0.05-13.07] | |
| Platelet count >150 × 109/L at inclusion | 34 (70.8) | 22 (81.5) | 12 (57.1) | 0.30 [0.08-1.11] | .07 |
| TPO-RA duration, median [IQR], y (n = 46) | 1.6 [1.0-3.8] | 2.0 [1.1-3.8] | 1.2 [0.9-3.2] | 0.95 [0.74-1.23] | .33 |
| TPO-RA drug class | .115 | ||||
| Eltrombopag | 40 (83.3) | 25 (92.6) | 15 (71.4) | 1 (reference) | |
| Romiplostim | 8 (16.7) | 2 (7.4) | 6 (28.6) | 5.00 [0.89-28.02] | |
| . | Total (n = 48)∗ . | SROT (n = 27) . | NSR (n = 21) . | Univariable analysis . | |
|---|---|---|---|---|---|
| Unadjusted—OR [95% CI] . | P value† . | ||||
| Age, median (IQR), y | 58.5 (41-73.5) | 58 (34-74) | 60 (51-71) | 1.01 [0.98-1.04] | .69 |
| No. of therapeutic lines before TPO-RAs, n = 48 | .98 | ||||
| 1 | 11 (23.0) | 6 (22.2) | 5 (23.8) | 1 (reference) | |
| ≥2 | 37 (77.0) | 21 (77.8) | 16 (76.2) | 0.98 [0.25-3.81] | |
| Splenectomy history | 6 (12.5) | 2 (7.4) | 4 (19.0) | 2.88 [0.47-17.54] | .25 |
| Previous treatment with rituximab | 22 (45.8) | 12 (44.4) | 10 (47.6) | 1.12 [0.36-3.53] | .85 |
| Previous treatment with another TPO-RA | 14 (29.2) | 6 (22.2) | 8 (38.1) | 2.44 [0.66-9.07] | .18 |
| ITP duration at TPO-RA initiation | .19 | ||||
| Persistent | 18 (37.5) | 12 (44.4) | 6 (28.6) | 1 (reference) | |
| Chronic | 30 (62.5) | 15 (55.6) | 15 (71.4) | 2.30 [0.66-8.01] | |
| ITP duration at inclusion | .87 | ||||
| Persistent | 2 (4.2) | 1 (3.7) | 1 (4.8) | 1 (reference) | |
| Chronic | 46 (95.8) | 26 (96.3) | 20 (95.2) | 0.77 [0.05-13.07] | |
| Platelet count >150 × 109/L at inclusion | 34 (70.8) | 22 (81.5) | 12 (57.1) | 0.30 [0.08-1.11] | .07 |
| TPO-RA duration, median [IQR], y (n = 46) | 1.6 [1.0-3.8] | 2.0 [1.1-3.8] | 1.2 [0.9-3.2] | 0.95 [0.74-1.23] | .33 |
| TPO-RA drug class | .115 | ||||
| Eltrombopag | 40 (83.3) | 25 (92.6) | 15 (71.4) | 1 (reference) | |
| Romiplostim | 8 (16.7) | 2 (7.4) | 6 (28.6) | 5.00 [0.89-28.02] | |